BOULDER, Colo.--(BUSINESS WIRE)--BaroFold Inc. announced today that it has initiated a two-stage Phase 1, repeat dosing, single-center, double-blinded study in up to sixty healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of BaroFeron™ (IFNß-1b).
